Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tech aims to spot dementia sooner in seniors

NCT ID NCT05723523

Knowledge-focused Sponsor: HealthPartners Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a computer program that helps primary care doctors identify older adults who might have early memory loss or dementia. Over 3,200 patients aged 65 and older took part. The tool uses information from electronic health records to flag patients who may need further evaluation, aiming to improve early detection and care planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clinical decision support software
What this could lead to
If successful, this tool could help doctors catch memory problems earlier, giving patients and families more time to plan care.
What could go wrong
This was a completed study, but the tool only helps with detection—it does not treat or slow the disease. Results may not apply to all clinics or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,230 people

The number who actually took part.

Started

Aug 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary care office visit at a randomized clinic during the accrual period, AND * Patient is age 65 or over, AND * Patient has no CI diagnosis documented in the EHR prior to the visit, AND * Patient has: * Any abnormal score on a comprehensive cognitive assessment (MoCA, MMSE or SLUMS) in the prior 18 months, OR * a MiniCog score of \<3 in the prior 18 months and there is no evidence of subsequent comprehensive cognitive assessment (MoCA, MMSE, SLUMS), OR * No cognitive testing in the last 18 months and a risk of a dementia diagnosis in the next 3 years \>=15% as calculated by the MC-PLUS algorithm developed in the R61 phase AND -First visit during the accrual period at which all prior inclusion criteria are met Exclusion Criteria: * Patient has received active parenteral chemotherapy within the last year * Patient has stage 4 or equivalent cancer diagnosis * Patient is enrolled in hospice care or palliative care program

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive impairment Dementia

Contacts and locations

Locations

  • HealthPartners

    Bloomington, Minnesota, 55425, United States

  • OCHIN, Inc.

    Portland, Oregon, 97201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.